Literature DB >> 17047388

Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1,000 operations.

Dieter K Ludecke1, Takumi Abe.   

Abstract

The aim of this short review is to inform about the possibilities and limits of transnasal microsurgery in acromegaly. The current reports on surgical remissions, according to the strict criteria with international consensus using age- and sex-related normal levels for insulin-like growth factor-I and suppression of growth hormone (GH) with oral glucose tolerance below 1 mug/l, are more or less agreeable with values between 34 and 74%. In microadenomas (<10 mm in diameter), 59-95% remissions are published. Some improvement might be achieved in macroadenomas which presently have a chance of 26-68% to be satisfactorily operated on. Special instruments introduced by us to visualize and remove partially invasive adenoma parts are described. Intraoperative magnetic resonance imaging is discussed. With intraoperative measurement of GH, small adenoma rests <3 mm can be diagnosed. When GH did not sufficiently decline, an additional tumor search resulted in a significant improvement in results in resectable macroadenomas. With these techniques, we achieved remission rates which can hardly be further increased (micros 95%, macros 68%). In grossly invasive grade 4 adenomas, which are frequent in our unit, only an 80-95% reduction in tumor mass is feasible. Preoperative treatment with somatostatin analogues as used in most of our patients reduces the comorbidity and facilitates adenoma removal which is still controversially discussed in the literature. The complication rate of microsurgery in experienced hands is low.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047388     DOI: 10.1159/000095533

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  23 in total

1.  Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against.

Authors:  M Losa; V G Crippa
Journal:  J Endocrinol Invest       Date:  2012-06       Impact factor: 4.256

2.  Endoscopic versus microscopic approach for surgical treatment of acromegaly.

Authors:  Hussein Fathalla; Michael D Cusimano; Antonio Di Ieva; John Lee; Omar Alsharif; Jeannette Goguen; Stanley Zhang; Harley Smyth
Journal:  Neurosurg Rev       Date:  2015-02-10       Impact factor: 3.042

3.  Nelfinavir induces radiation sensitization in pituitary adenoma cells.

Authors:  Jing Zeng; Alfred P See; Khaled Aziz; Saravanan Thiyagarajan; Tarek Salih; Rajendra P Gajula; Michael Armour; Jillian Phallen; Stephanie Terezakis; Lawrence Kleinberg; Kristen Redmond; Russell K Hales; Roberto Salvatori; Alfredo Quinones-Hinojosa; Phuoc T Tran; Michael Lim
Journal:  Cancer Biol Ther       Date:  2011-10-01       Impact factor: 4.742

4.  Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission.

Authors:  Samuel S Shin; Matthew J Tormenti; Alessandro Paluzzi; William E Rothfus; Yue-Fang Chang; Hanady Zainah; Juan C Fernandez-Miranda; Carl H Snyderman; Sue M Challinor; Paul A Gardner
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

5.  Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications.

Authors:  Thomas J Wilson; Erin L McKean; Ariel L Barkan; William F Chandler; Stephen E Sullivan
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 6.  The surgical treatment of acromegaly.

Authors:  Michael Buchfelder; Sven-Martin Schlaffer
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

7.  Surgical results of growth hormone-secreting pituitary adenoma.

Authors:  Min-Su Kim; Hyun-Dong Jang; Oh-Lyong Kim
Journal:  J Korean Neurosurg Soc       Date:  2009-05-31

8.  Olfactory neuroblastoma following treatment for pituitary adenoma.

Authors:  Kyung-Jae Park; Shin-Hyuk Kang; Hoon-Gab Lee; Yong-Gu Chung
Journal:  J Neurooncol       Date:  2008-08-05       Impact factor: 4.130

Review 9.  Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.

Authors:  Richard A Feelders; Leo J Hofland; Maarten O van Aken; Sebastian J Neggers; Steven W J Lamberts; Wouter W de Herder; Aart-Jan van der Lely
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

10.  Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes A Romijn
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.